Lipocine Inc.
corporate_fare Company Profile
Lipocine Inc. (NASDAQ:LPCN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for LPCN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for LPCN spans 4, 10-Q, 8-K, DEFA14A.
Recent high-impact activity:
- Director Higuchi Buys 150,000 LPCN Shares for $225,225 on the Open Market
- Lipocine CEO Mahesh Patel Buys 50,000 Shares for $79,488 Open-Market
- Lipocine Q3 Loss Narrows to $0.7M on $2.3M Revenue; $21.5M Cash Funds Runway to Nov 2027
- Lipocine Swings to Near-Breakeven as Q3 Revenue Jumps to $2.3M
- Health Canada Clears Lipocine's TLANDO, Setting Stage for Year-End Launch
Financial Snapshot
Short Interest & Short Volume
1.50 days to coverFINRA reported short interest of 325,401 shares in LPCN as of the October 30, 2026 settlement, a 7.4% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 15.0% of LPCN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for LPCN, detected from its recent SEC filings.
ATM Sales Agent Fee Increased · Existing ATM Program Context
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →